<DOC>
	<DOCNO>NCT01075425</DOCNO>
	<brief_summary>RATIONALE : Belinostat bortezomib may stop growth cancer cell block enzymes need cell growth . Giving belinostat together bortezomib may kill cancer cell . PURPOSE : This phase I trial study side effect best dose give belinostat together bortezomib treat patient relapsed refractory acute leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>Belinostat Bortezomib Treating Patients With Relapsed Refractory Acute Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine recommended phase II dose combination bortezomib belinostat patient relapse refractory acute leukemia ( AL ) , myelodysplasia ( MDS ) , chronic myelogenous leukemia blast crisis . SECONDARY OBJECTIVES : I . Determine safety tolerance describe toxicity combination . II . To demonstrate adequate method assessment pharmacodynamic response leukemia cell bone marrow and/or peripheral blood term effect NF-kB ( nuclear RelA immunofluorescence microscopy ) , NF-kB dependent protein XIAP Bcl-xL , BIM , document pharmacodynamic response observe course study . III . To document activity combination observe course study . OUTLINE : Patients receive belinostat IV 30 minute day 1-5 8-12 bortezomib IV day 1 , 4 , 8 , 11 . Treatment repeat every 21 day 12 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Inclusion Relapsed refractory acute leukemia acute myeloid leukemia ( AML ) APL acute lymphocytic leukemia ( ALL ) acute leukemia evolve prior myelodysplastic syndrome requirement prior therapy myelodysplastic Syndrome ( MDS ) International Prognostic Scoring System ( IPSS ) intermediate2 great chronic myelogenous leukemia myeloid lymphoid blast crisis WBC = &lt; 50 x 10^9/L ; hydroxyurea leukopheresis may use prior start treatment Prior allogeneic stem cell transplant allow provide &gt; /= 12 month elapse since allogeneic transplant ; graft versus host disease present ; currently immunosuppressive therapy AST , ALT = &lt; 2.5 x upper limit normal ( ULN ) Female subject postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , oral injectable hormonal method ; barrier method intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study Male subject agree use acceptable method contraception duration study Serum total bilirubin = &lt; 1.5 x upper limit normal Serum potassium &gt; = 3.5 mEq/L serum magnesium &gt; = 1.7 mEq/dL ( electrolyte may correct supplementation ) ECOG Performance Status ( PS ) = &lt; 2 Creatinine = &lt; 1.5 x upper limit normal calculate actual creatinine clearance &gt; 45 mL/min Exclusion Willing medically suitable remission induction agent anticipation potentially curative allogeneic bone marrow transplant Known CNS malignant disease Prior severe allergic reaction bortezomib , mannitol , boron , belinostat compound hydroxamate class arginine Grade 1 pain Grade &gt; = 2 peripheral neuropathy paresthesia within 14 day enrollment History sustain ventricular tachycardia , ventricular fibrillation , Torsade de Pointes , resuscitate cardiac arrest â€¢ History resuscitate cardiac arrest . Note : person without preexist cardiovascular comorbidities experience resuscitated cardiac arrest set sepsis ARE eligible provide residual cardiac abnormality provide require ongoing medication manage cardiac issue outcome event . Conduction abnormality concomitant treatment antiarrhythmic agent prevent control arrhythmia Known congenital long QT syndrome Clinically significant infection include infection HIV , active hepatitis B C Significant cardiovascular disease , hypertrophic cardiomegaly restrictive cardiomyopathy , myocardial infarction within past 6 month , unstable angina Baseline QTc interval &gt; 450 msec Planned ongoing treatment drug may risk cause Torsades de Pointes Persistent blood pressure ( BP ) &gt; =160/95 Serious medical psychiatric illness likely interfere patient participation Pregnant nursing Diagnosis treatment another malignancy within 3 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , low risk prostate cancer curative therapy Planned ongoing treatment drug think potentially adversely interact belinostat Strong moderate CYP3A4 inhibitor Patient receive investigational drug within 14 day enrollment If steroid cancer control use , patient must agent &gt; /= 1 week start treatment . Exception : maintenance therapy nonmalignant disease prednisone steroid equivalent dose &lt; 10 mg/day permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>leukemia</keyword>
	<keyword>acute leukemia</keyword>
	<keyword>chronic myelogenous leukemia</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>relapse acute leukemia</keyword>
	<keyword>refractory acute leukemia</keyword>
	<keyword>belinostat</keyword>
	<keyword>bortezomib</keyword>
	<keyword>Velcade</keyword>
	<keyword>PXD-101</keyword>
</DOC>